Trial Profile
Accompanying research of Phase II study of atezolizumab for advanced non-small-cell lung cancer patients not indicative of cytotoxic chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms 2130-A
- 27 Jun 2021 Status changed from recruiting to discontinued.
- 11 Jul 2018 New trial record